Initial Experience, Safety, and Feasibility of Left Bundle Branch Area Pacing: A Multicenter Prospective Study.


Journal

JACC. Clinical electrophysiology
ISSN: 2405-5018
Titre abrégé: JACC Clin Electrophysiol
Pays: United States
ID NLM: 101656995

Informations de publication

Date de publication:
12 2020
Historique:
received: 07 05 2020
revised: 19 06 2020
accepted: 05 07 2020
entrez: 28 12 2020
pubmed: 29 12 2020
medline: 19 8 2021
Statut: ppublish

Résumé

This study sought to evaluate the safety and feasibility of conduction system pacing by performing left bundle branch area pacing (LBBAP). There are limited data from single centers showing that LBBAP may circumvent the technical and electrophysiological challenges encountered with His bundle pacing. Patients referred for pacemaker implantation at 2 centers between February 1, 2019, and March 31, 2020, were considered for LBBAP. LBBAP was performed by implanting a lumen-less, exposed helix lead approximately 2 cm distal to the His bundle and deep into the septum using a specialized delivery sheath. Implant success rates, complications, and electrophysiological parameters were assessed. LBBAP was successful in 305 of 341 patients (89%). Mean age was 72 ± 12 years; 45% were women; and 39% had QRS duration (QRSd) >130 ms, 22% right bundle branch block, 11% left bundle branch block, and 6% intraventricular conduction defect. Pacing indications were sinus node dysfunction in 28.7%, atrioventricular block in 52.5%, cardiac resynchronization therapy in 8.8%, and refractory atrial fibrillation in 10% of patients. Procedural duration was 74.7 ± 34 min and fluoroscopic time was 10.4 ± 8.1 min. The mean baseline QRSd and paced QRSd in the overall cohort was 114 ± 29.8 ms versus 112 ± 11.7 ms (p < 0.001) and in patients with infra-Hisian disease was 144.5 ± 19 ms versus 115 ± 12 ms (p < 0.001), respectively. Mean left ventricular activation time was 71.7 ± 11 ms at high output and 74.7 ± 11 ms at low output. LBB potentials were noted in 41% patients. Pacing threshold and R waves were 0.74 ± 0.3 V at 0.4 ms and 10.7 ± 4.9 mV at time of implantation and were stable at 1-, 3-, 6-, and 12-month follow-ups. The only major complications were 3 LBBAP lead dislodgements, 2 within 24 h and 1 at 2 weeks. LBBA pacing is safe, feasible, and a reliable alternative to His bundle pacing for providing physiological pacing. Randomized controlled studies are needed to confirm the safety, feasibility, and clinical outcomes of LBBAP.

Sections du résumé

OBJECTIVES
This study sought to evaluate the safety and feasibility of conduction system pacing by performing left bundle branch area pacing (LBBAP).
BACKGROUND
There are limited data from single centers showing that LBBAP may circumvent the technical and electrophysiological challenges encountered with His bundle pacing.
METHODS
Patients referred for pacemaker implantation at 2 centers between February 1, 2019, and March 31, 2020, were considered for LBBAP. LBBAP was performed by implanting a lumen-less, exposed helix lead approximately 2 cm distal to the His bundle and deep into the septum using a specialized delivery sheath. Implant success rates, complications, and electrophysiological parameters were assessed.
RESULTS
LBBAP was successful in 305 of 341 patients (89%). Mean age was 72 ± 12 years; 45% were women; and 39% had QRS duration (QRSd) >130 ms, 22% right bundle branch block, 11% left bundle branch block, and 6% intraventricular conduction defect. Pacing indications were sinus node dysfunction in 28.7%, atrioventricular block in 52.5%, cardiac resynchronization therapy in 8.8%, and refractory atrial fibrillation in 10% of patients. Procedural duration was 74.7 ± 34 min and fluoroscopic time was 10.4 ± 8.1 min. The mean baseline QRSd and paced QRSd in the overall cohort was 114 ± 29.8 ms versus 112 ± 11.7 ms (p < 0.001) and in patients with infra-Hisian disease was 144.5 ± 19 ms versus 115 ± 12 ms (p < 0.001), respectively. Mean left ventricular activation time was 71.7 ± 11 ms at high output and 74.7 ± 11 ms at low output. LBB potentials were noted in 41% patients. Pacing threshold and R waves were 0.74 ± 0.3 V at 0.4 ms and 10.7 ± 4.9 mV at time of implantation and were stable at 1-, 3-, 6-, and 12-month follow-ups. The only major complications were 3 LBBAP lead dislodgements, 2 within 24 h and 1 at 2 weeks.
CONCLUSIONS
LBBA pacing is safe, feasible, and a reliable alternative to His bundle pacing for providing physiological pacing. Randomized controlled studies are needed to confirm the safety, feasibility, and clinical outcomes of LBBAP.

Identifiants

pubmed: 33357573
pii: S2405-500X(20)30602-2
doi: 10.1016/j.jacep.2020.07.004
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1773-1782

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Author Disclosures Dr. Padala has served as a consultant for Medtronic. Dr. Koneru has received teaching honoraria from Medtronic and Biotronik; and has received fellowship support from Boston Scientific, Biosense Webster, Medtronic, and Abbott Medical. Dr. Ellenbogen has served as a consultant and Data and Safety Monitoring Board chair for Medtronic; and honoraria and research support from Medtronic. Dr. Verma has served as a consultant for Medtronic, Biosense Webster, Boston Scientific, and Servier; and has received grant support from Bayer and Biotronik. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Santosh K Padala (SK)

Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA. Electronic address: santosh.padala@vcuhealth.org.

Vivak M Master (VM)

Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.

Maria Terricabras (M)

Division of Cardiology, Southlake Regional Health Center, University of Toronto, Toronto, Ontario, Canada.

Andrea Chiocchini (A)

Division of Cardiology, Southlake Regional Health Center, University of Toronto, Toronto, Ontario, Canada.

Aatish Garg (A)

Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.

Jordana Kron (J)

Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.

Richard Shepard (R)

Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.

Gautham Kalahasty (G)

Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.

Zahara Azizi (Z)

Division of Cardiology, Southlake Regional Health Center, University of Toronto, Toronto, Ontario, Canada.

Bernice Tsang (B)

Division of Cardiology, Southlake Regional Health Center, University of Toronto, Toronto, Ontario, Canada.

Yaariv Khaykin (Y)

Division of Cardiology, Southlake Regional Health Center, University of Toronto, Toronto, Ontario, Canada.

Alfredo Pantano (A)

Division of Cardiology, Southlake Regional Health Center, University of Toronto, Toronto, Ontario, Canada.

Jayanthi N Koneru (JN)

Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.

Kenneth A Ellenbogen (KA)

Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.

Atul Verma (A)

Division of Cardiology, Southlake Regional Health Center, University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH